PharmaMar signs licensing agreement with Eczacıbasi Group for Aplidin

PharmaMar has signed agreement with Eczacibasi Group to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey. Aplidin is PharmaMar´s second most advanced anticancer drug currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma.

Under the terms of the agreement, PharmaMar will receive an upfront payment as well as development milestones related to the health approval procedure of Aplidin in this country. PharmaMar will retain exclusive production rights and will supply the finished product to Eczacibasi for commercial use.

PharmaMar´s MD Oncology Business Unit, Luis Mora said that the partnership with Eczacibasi will help in the commercialization in Turkey of plitidepsin, developed to tackle hematologic cancer. they are looking forward to working with one of the leading Health Care companies in this country. They are firmly committed to advancing in the development of innovative oncology therapies.

Eczacibasi Group CEO and President, Atalay Gümrah said that “the agreement between PharmaMar and Eczacibasi Pharmaceuticals Marketing (EIP) offered a major advance for healthcare in Turkey, as Aplidin represented the latest innovation in cancer treatment.